Abstracts tagged "Lupus"

Abstract Number: 844 • 2017 ACR/ARHP Annual Meeting
Social Support, Stress and Health Outcomes in Systemic Lupus Erythematosus: Georgians Organized Against Lupus (GOAL) Cohort
Charmayne M. Dunlop-Thomas, S. Sam Lim, Gaobin Bao and Cristina Drenkard, Division of Rheumatology, Emory University School of Medicine, Atlanta, GA
Background/Purpose: Stress can influence immune and neuroendocrine processes, and may lead to poor outcomes in people with systemic lupus erythematosus (SLE). Social support can potentially…
Abstract Number: 1616 • 2017 ACR/ARHP Annual Meeting
Early and Late Onset Biopsy Proven Lupus Nephritis without Other Associated Autoimmune Diseases: Severity and Long-Term Outcome
Michelle Lopes¹, Laryssa Santos², Luciana Seguro³ and Eloisa Bonfa⁴, ¹Rheumatology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ²Rheumatology, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR, São Paulo, Brazil, ³Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ⁴Rheumatology Divison, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
Background/Purpose: Lupus nephritis (LN) usually develops within the first years of Systemic Lupus Erythematosus (SLE) onset and rarely after that. There are scarce studies comparing…
Abstract Number: 2123 • 2017 ACR/ARHP Annual Meeting
Protein-Losing Enteropathy in Patients with Systemic Autoimmune Diseases: Characterization of 263 Cases (GEAS-SEMI Spanish Cohort)
Alejandra Flores-Chavez^1,2,3, Soledad Retamozo^4,5,6, Angel Robles⁷, Guadalupe Fraile Rodriguez⁸, Sofia Arteaga^9,10, Celeste Galceran-Chaves¹¹, Roberto Pérez-Alvarez¹², Marta Pérez de Lis¹², Belchin Kostov¹³, Manuel Ramos-Casals^14,15 and Pilar Brito-Zerón^14,16, ¹Department of Autoimmune Diseases, ICMiD, Hospital Clínic Barcelona, Spain., Barcelona, Spain, ²Unidad de Investigación Biomédica 02 (Unidad de Investigación en Epidemiología Clínica), UMAE, Hospital de Especialidades, Centro Médico Nacional de Occidente, Instituto Mexicano del Seguro Social, Jalisco, Mexico, ³Programa de Doctorado en Ciencias Médicas, Centro Universitario de Investigaciones Biomédicas (CUIB), Universidad de Colima, Colima, Mexico, Mexico, Mexico, ⁴Instituto de Investigaciones en Ciencias de la Salud, Universidad Nacional de Córdoba, Consejo Nacional de Investigaciones Científicas y Técnicas (INICSA-UNC-CONICET), Cordoba, Argentina, ⁵Laboratory of Systemic Autoimmune Diseases “Josep Font”, CELLEX, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Department of Systemic Autoimmune Diseases, ICMID, Hospital Clinic, Barcelona, Barcelona, Spain, ⁶Rheumatology Unit, Hospital Privado Universitario de Córdoba, Institute University of Biomedical Sciences University of Córdoba (IUCBC), Cordoba, Argentina, ⁷Department of Internal Medicine, Hospital La Paz, Madrid, Madrid, Spain, ⁸Internal Medicine, Hospital Ramón y Cajal, Madrid, Madrid, Spain, ⁹Department of Autoimmune Diseases, ICMiD, Hospital Clínic Barcelona, Barcelona, Spain, ¹⁰Universidad de Antioquía, Medellín, Colombia, Medellin, Colombia, ¹¹Neuroscience Clinical Institute, Hospital Clínic, Barcelona, Barcelona, Spain, ¹²Department of Internal Medicine, Hospital Alvaro Cunqueiro, Vigo, Vigo, Spain, ¹³Primary Care Research Group, IDIBAPS, Centre d’Assistència Primària ABS Les Corts, CAPSE, Barcelona, Barcelona, Spain, ¹⁴Laboratory of Systemic Autoimmune Diseases “Josep Font”, CELLEX, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Department of Systemic Autoimmune Diseases, ICMID, Hospital Clinic, Barcelona, Spain, Barcelona, Spain, ¹⁵Department of Medicine, University of Barcelona, Barcelona, Spain., Barcelona, Spain, ¹⁶Autoimmune Diseases Unit, Department of Medicine, Hospital CIMA- Sanitas, Barcelona., Bacelona, Spain
Background/Purpose: Protein-losing enteropathy (PLE) is a rare condition characterized by a loss of serum protein into the gastrointestinal tract resulting in hypoproteinemia, which can be…
Abstract Number: 2818 • 2017 ACR/ARHP Annual Meeting
Gene Expression Analysis Demonstrates That Multiple Type 1 Interferons Are Involved in Lupus Pathogenesis
Michelle Catalina¹, Prathyusha Bachali², Sushma Madamanchi¹, Amrie Grammer¹ and Peter Lipsky¹, ¹Ampel BioSolutions LLC, Charlottesville, VA, ²Ampel BioSolutions LLC, Charlottesville, MA
Background/Purpose: A role for interferon (IFN) in lupus pathogenesis has been inferred from the prominent IFN gene signature (IGS) found in lupus peripheral blood. However,…
Abstract Number: 897 • 2017 ACR/ARHP Annual Meeting
Cutaneous Lupus Is Driven By an Exaggerated Interferon Kappa Loop Which Primes for Interferon Alpha Responses
Johann Gudjonsson¹, Mrinal Sarkar¹, Alex Tsoi², Celine C. Berthier³, Grace Hile⁴, Yun Liang⁴, Jianhua Liu⁵, Paul Harms⁶ and J. Michelle Kahlenberg⁷, ¹Dermatology, University of Michigan, Ann Arbor, MI, ²Departments of Dermatology and Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, MI, ³Nephrology, Division of Nephrology, University of Michigan Medical Center, Ann Arbor, MI, ⁴University of Michigan, Ann Arbor, MI, ⁵Internal Medicine, Division of Rheumatology, University of Michigan, Ann Arbor, MI, ⁶Pathology, University of Michigan, Ann Arbor, MI, ⁷Internal Medicine, Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI
Background/Purpose: Cutaneous inflammation is a common and disfiguring manifestation for 70% of patients with systemic lupus erythematosus, yet our understanding of the pathogenesis of cutaneous…
Abstract Number: 1618 • 2017 ACR/ARHP Annual Meeting
Risk Factors for Development of Early Infectious and Non-Infectious Complications in Systemic Lupus Erythematosus Patients Undergoing Major Surgery
Lauro Quintanilla-González¹, Gonzalo Torres-Villalobos² and Andrea Hinojosa-Azaola³, ¹Immunology & Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²Departmen of Experimental Surgery, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ³Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
Background/Purpose: Systemic Lupus Erythematosus (SLE) is an autoimmune disease with increased cardiovascular and infectious complications due to subclinical atherosclerosis, disease activity and treatment-related factors. The…
Abstract Number: 2559 • 2017 ACR/ARHP Annual Meeting
KZR-616, a Selective Inhibitor of the Immunoproteasome, Blocks the Disease Progression in Multiple Models of Systemic Lupus Erythematosus (SLE)
Tony Muchamuel¹, Janet Anderl², R Andrea Fan², Henry W. B. Johnson³, Christopher J Kirk⁴ and Eric Lowe², ¹Pharmacology and Toxicology, Kezar Life Sciences, South San Francisco, CA, ²Biology, Kezar Life Sciences, South San Francisco, CA, ³Medicinal Chemistry, Kezar Life Sciences, South San Francisco, CA, ⁴Kezar Life Sciences, South San Francisco, CA
Background/Purpose: The proteasome inhibitor bortezomib has been used successfully to treat patients with SLE. The immunoproteasome is a distinct class of proteasome found predominantly in…
Abstract Number: 2986 • 2017 ACR/ARHP Annual Meeting
Omega Polyunsaturated Fatty Acids and Systemic Lupus Erythematosus (SLE): the Michigan Lupus Epidemiology & Surveillance (MILES) Program
Prae Charoenwoodhipong¹, Suzanna Zick², Wendy Marder³, Afton L. Hassett⁴, W. Joseph McCune⁵, Caroline Gordon⁶, Siobán Harlow⁷ and Emily C. Somers³, ¹University of Michigan, Ann Arbor, MI, ²Department of Family Medicine, University of Michigan, Ann Arbor, MI, ³Internal Medicine-Rheumatology, University of Michigan, Ann Arbor, MI, ⁴Rheumatology, Emory University, Atlanta, GA, ⁵Int Med/ Rheum, University of Michigan, Ann Arbor, MI, ⁶Rheumatology Research Group, Institute of Inflammation and Ageing,, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom, ⁷Epidemiology Department- School of Public Health, Obstetrics and Gynecology- Medical School, University of Michigan, Ann Arbor, MI
Background/Purpose: Omega fatty acids have immunomodulatory properties; omega-3 (n-3) fatty acids are generally anti-inflammatory and omega-6 (n-6) pro-inflammatory. High n-6:n-3 ratios (up to 16:1) are…
Abstract Number: 223 • 2017 ACR/ARHP Annual Meeting
Decreased Medication Adherence Is a Major Cause for Increased Risk of Hospitalizations Among High Risk Lupus Patients
Caroline Thirukumaran¹, Katherine McCarthy², Jessica Patel³ and Allen P. Anandarajah⁴, ¹orthopedics, University of Rochester Medical Center, Rochester, NY, ²Pharmacy, University of Rochester Medical Center, Rochester, NY, ³Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, NY, ⁴Dept of Rheumatology, Univ of Rochester Medical Ctr, Rochester, NY
Background/Purpose: Low medication adherence in lupus has been associated with increased hospitalizations, more severe disease activity, and irreversible multi-organ damage. While lower socioeconomic levels, education,…
Abstract Number: 898 • 2017 ACR/ARHP Annual Meeting
B Cell Specific TLR9 Suppresses Disease in Murine Lupus
Jeremy Tilstra¹, Rachael Gordon², Shinu John³, Brady Marburger², Sheldon Bastacky⁴, Kevin Nickerson² and Mark Shlomchik⁵, ¹Rheumatology, Univ of Pittsburgh Medical Center, Pittsburgh, PA, ²University of Pittsburgh, Pittsburgh, PA, ³Moderna Therapeutics, Cambridge, MA, ⁴Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA, ⁵Immunology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Toll-like receptor (TLR) signaling is a central to lupus pathogenesis. GWAS studies have repeatedly identified components of TLR signaling pathway in SLE patients. Furthermore,…
Abstract Number: 1626 • 2017 ACR/ARHP Annual Meeting
Childhood-Onset Predicts Increased Steroid-Related Damage Among Adults with Systemic Lupus Erythematosus
Merav Heshin-Bekenstein¹, Emily von Scheven², Aimee O. Hersh³, Laura Trupin⁴, Edward H. Yelin⁴ and Erica Lawson¹, ¹Pediatric Rheumatology, University of California San Francisco, San Francisco, CA, ²Division of Rheumatology, Department of Pediatrics, University of California San Francisco, San Francisco, CA, ³Pediatrics/Rheumatology, University of Utah, Salt Lake City, UT, ⁴Medicine/Rheumatology, University of California San Francisco, San Francisco, CA
Background/Purpose: Childhood-onset SLE (cSLE) often presents with severe disease, managed with high-dose steroids. However, little is known about differences in long-term steroid toxicity between adults…
Abstract Number: 2562 • 2017 ACR/ARHP Annual Meeting
Inhibition of Spleen Tyrosine Kinase Improves Renal Pathology and Reduces Lymphocyte Activation in the MRL/Lpr and NZB/NZW Murine Models of Systemic Lupus Erythematosus
Julie Di Paolo¹, Christopher Pohlmeyer¹, Zhi-Hua Cui², Gundula Min-Oo¹, Igor Mikaelian³, Robert Brockett³, Bernard Murray⁴, Roy Bannister⁵, JiYun Kim⁶ and Franziska Matzkies⁷, ¹Immunology and Inflammation Biology, Gilead Sciences, Foster City, CA, ²Fibrosis Biology, Gilead Sciences, Foster City, CA, ³Biology Core Support, Gilead Sciences, Foster City, CA, ⁴DMPK, Gilead Sciences, Foster City, CA, ⁵Drug Safety, Gilead Sciences, Foster City, CA, ⁶Biomarkers, Gilead Sciences, Foster City, CA, ⁷Gilead Sciences, Foster City, CA
Background/Purpose: Spleen tyrosine kinase (SYK) mediates immunoreceptor signaling in hematopoietic cells important in the initiation and progression of systemic lupus erythematosus (SLE), including those from…
Abstract Number: 232 • 2017 ACR/ARHP Annual Meeting
The Charla De Lupus (Lupus Chat)® Program: Assessing the Needs of Teens and Young Adults with Lupus and Their Caregivers to Develop a Family Model Nutrition and Fitness Intervention
Melissa T. Flores¹, Jillian Rose², Priscilla Toral¹, Lillian Mendez¹, Dariana M. Pichardo¹, Roberta Horton¹ and Lisa F. Imundo³, ¹Social Work Programs, Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, New York, NY, ³Pediatrics, Columbia University Medical Center, New York, NY
Background/Purpose: Studies show Hispanics/Latinos are significantly impacted by health disparities, with higher rates of obesity & diabetes than Whites. Combined with SLE & higher risk…
Abstract Number: 920 • 2017 ACR/ARHP Annual Meeting
Area-Level Predictors of Medication Nonadherence Among U.S. Medicaid Beneficiaries with Lupus: A Multilevel Study
Candace H. Feldman¹, Karen H. Costenbader², Daniel H. Solomon³, S.V. Subramanian⁴ and Ichiro Kawachi⁵, ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ³Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁴Social and Behavioral Sciences, Harvard T.H. Chan School of Public Health, Boston, MA, ⁵Social and Behavioral Sciences, Harvard T. H. Chan School of Public Health, Boston, MA
Background/Purpose: Among lupus patients, adherence to hydroxychloroquine (HCQ), the backbone of therapy, remains suboptimal. Individual-level factors, including younger age, poverty, and black race, have been…
Abstract Number: 1643 • 2017 ACR/ARHP Annual Meeting
15 Year Comparative Analysis of Cardiovascular Events in Female Subjects with Lupus Versus Controls
Erika Joyce¹, Kristy Huysman², Linda Santelices², Michael Anderson², Amy H. Kao³, Jennifer Elliott⁴, Jennifer Mall², Amy Xiaoqin Tang⁵ and Susan Manzi², ¹Internal Medicine, Allegheny Health Network, Pittsburgh, PA, ²Medicine, Allegheny Health Network, Pittsburgh, PA, ³EMD Serono Research & Development Institute, Inc. (a business of Merck KGaA, Darmstadt, Germany), Billerica, MA, ⁴Allegheny Health Network, Pittsburgh, PA, ⁵Lupus Center of Excellence, Allegheny Health Network Research Institute, Pittsburgh, PA
Background/Purpose: The multi-organ sequelae of systemic lupus erythematosus (SLE) may include nephritis, alveolar hemorrhage, and cardiovascular disease. Our long term follow up of female SLE…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].